The strength of TheraMe!’s team is its interdisciplinary expertise

Our team includes University Professors in Microfluidics and Bioinformatics, as well as experts in entrepreneurship, business administration, cancer biology and biomedical sciences.

Board of Directors

  • Dr Pierre-Edouard Sottas has built his 25-year career on one idea: health decisions should rest on the individual, not on the population average. He created the biological passport approach, which assesses each person against their own biological profile, and applied it to clinical trials, early disease detection and anti-doping, where he led the rollout of the Athlete Biological Passport in more than 120 countries. He then built and led four healthcare and diagnostics companies that brought tests and products to market under European and US frameworks (CE, FDA, CLIA, CAP). As CEO, he now leads TheraMe, which applies the same principle to cancer: it measures how a patient’s own living tumour cells respond to drugs, so that this measurement becomes part of routine treatment decisions.

  • Hana Samet is the co-founder and CTO of TheraMe! and holds a Master’s degree in Microengineering from EPFL. Active in the startup ecosystem since 2018, she has helped build early-stage MedTech ventures, combining technical expertise with hands-on experience in product development and entrepreneurship. At EPFL, she contributed to the development and patenting of innovative microfluidic technology for personalized cancer care. Today, she leads the development and industrialization of TheraMe!’s functional drug-screening platform, bringing together multidisciplinary teams and industrial partners to translate scientific innovation into practical medical technologies. Beyond TheraMe!, she serves on the Board of Directors of the Swiss Startup Association, actively contributing to Switzerland’s entrepreneurial ecosystem.

  • Dr. Claudia Giani-Leber has built her career across investment management, entrepreneurship and contemporary art. She studied art history, Italian and modern German literature at the University of Basel, earning her doctorate with a thesis on Swiss painter Alfred Heinrich Pellegrini. In 1994, she founded what is now ACATIS Investment KVG mbH, where she serves as Managing Director responsible for marketing and public relations. She has also run Arte Giani, a contemporary art gallery in Frankfurt, since 1994.

Management & Team

  • Dr Pierre-Edouard Sottas has built his 25-year career on one idea: health decisions should rest on the individual, not on the population average. He created the biological passport approach, which assesses each person against their own biological profile, and applied it to clinical trials, early disease detection and anti-doping, where he led the rollout of the Athlete Biological Passport in more than 120 countries. He then built and led four healthcare and diagnostics companies that brought tests and products to market under European and US frameworks (CE, FDA, CLIA, CAP). As CEO, he now leads TheraMe, which applies the same principle to cancer: it measures how a patient’s own living tumour cells respond to drugs, so that this measurement becomes part of routine treatment decisions.

  • Prof. Christoph A. Merten is a Professor of Biomedical Microfluidics at EPFL and holds an adjunct position at the Ludwig Institute for Cancer Research. His research focuses on developing innovative microfluidic technologies for drug discovery and personalized cancer therapy. Combining engineering, biology and high-throughput screening, he has pioneered approaches to test drug combinations directly on patient tumour samples. Alongside his academic career, he is also the sole scientific founder of Velabs Therapeutics, now operating as Veraxa Biotech. As co-founder of TheraMe!, he brings his scientific expertise and entrepreneurial experience to advancing functional drug screening, with the goal of making personalized cancer treatment decisions more accessible in clinical practice..

  • Hana Samet is the co-founder and CTO of TheraMe! and holds a Master’s degree in Microengineering from EPFL. Active in the startup ecosystem since 2018, she has helped build early-stage MedTech ventures, combining technical expertise with hands-on experience in product development and entrepreneurship. At EPFL, she contributed to the development and patenting of innovative microfluidic technology for personalized cancer care. Today, she leads the development and industrialization of TheraMe!’s functional drug-screening platform, bringing together multidisciplinary teams and industrial partners to translate scientific innovation into practical medical technologies. Beyond TheraMe!, she serves on the Board of Directors of the Swiss Startup Association, actively contributing to Switzerland’s entrepreneurial ecosystem.

  • Dr. Ngoc-Hien Du is a molecular biologist and one of the co-founders of TheraMe!, with extensive research experience in genetics, transcriptomics, and gene regulation. Her academic work at the Universities of Lausanne and Zurich has explored the molecular mechanisms underlying circadian rhythms and their individual differences linked to human disease. She has contributed to scientific research using multi-omic approaches to understand genetics, gene expression, and metabolism. As the CIO of TheraMe!, she brings this expertise to functional precision oncology, connecting experimental drug responses with molecular insights from patient-derived tumour cells to advance personalized cancer treatment.

  • Vivien Streit is bringing over eight years of experience in medical devices and embedded systems. With a Master’s degree in Microengineering from EPFL, he has contributed in developing regulated software under ISO 13485 and IEC 62304, from prototypes to market-ready solutions.

  • As theraMe!’s Lab Manager, Stéphane responsible for setting up and running our lab. With deep NGS experience, he supports compliance, documentation, and translational workflows across biology and clinical teams. Previously, Stéphane worked in the sequencing facility at the Friedrich Miescher Institute (FMI), a leading Swiss centre for genomics and molecular biology research.

  • Penelope brings over seven years of experience in preclinical pharmaceutical R&D, including work in GxP-regulated industry, academia (EPFL), and clinical research (CHUV). With a background in pharmaceutical technologies and life science management, she supports clinical development activities at TheraMe!.

  • Mehmet Sehir, a bioinformatician, specializes in NGS data analysis and variant calling pipeline development. He holds an MSc in Bioinformatics and Data Analysis from the University of Geneva and gained significant experience at HUG, developing pipelines and working on data analysis and visualization with Python and R.

  • Raffaele is a computational biologist specialized in the application of machine learning techniques to perturbational and systems pharmacology. He holds a PhD in Computational Biology from Human Technopole and the University of Milan and has developed strong expertise in bioinformatics, data science, viability screen data analysis, and the integration of complex biological datasets.

  • As an Biomedical Engineer, Francesca contributes to the testing and optimization of our microfluidic systems and workflows for high-throughput drug testing. With a background in biomedical engineering, organ-on-chip technology, and applied research gained during her internship at CSEM, she bridges bioengineering and translational research to advance personalized therapy solutions.

  • Nicola is an EPFL alumna with a Master's degree in Robotics. She has experience developing embedded systems, desktop applications, web platforms, and connected consumer devices, including a commercial product successfully launched to market. At TheraMe!, she contributes to embedded software development, drawing on her multidisciplinary background in robotics and software engineering to build reliable and innovative technologies.

  • Simona is a medical biotechnologist with a PhD in Systems Biology and a CAS in Clinical Research, bringing over seven years of experience in clinical study management with a strong scientific background in oncology and biomarker research. Her expertise includes clinical operations, clinical data management, and regulatory compliance in both hospital and industry. At TheraMe!, she supports the clinical affairs activities of the company.

Scientific Advisors

  • Prof. Federica Eduati is an Assistant Professor of Systems Biology for Oncology at Eindhoven University of Technology in the Netherlands. She is an expert in personalized cancer therapies. Her approach combines both data science and experimental methods.

  • Dr. med. Michael Quante is GI fellow and principle investigator at the University hospital of Freiburg. His lab is focusing on a translational research approach on Barrett's Esophagus and esophageal adenocarcinoma. He is working to facilitate the clinical realization of basic science principles in order to improve the care and treatment of esophagus cancer patients and the surveillance of patients with Barrett's Esophagus.

Consultants

  • Dr. Bence Szalai is bioinformatics consultant at TheraMe!. He develops the workflows to analyse the data coming from TheraMe! screens. Previously, during his post-doc fellowships he worked extensively with cancer gene expression and drug sensitivity data.

  • Dr. Delamarche is an independent consultant, Licensing Manager at Knowledge Transfer Unil CHUV, and Lecturer at ETH Zurich. Through his 31 years in the industry (IBM Research Zurich, start-ups), Dr. Delamarche made pioneering contributions to the field of microfluidics and worked on many bioanalytical, medtech, and in vitro diagnostic projects. He is passionate about applied research and a contributor to scientific panels for governmental agencies and large research institutions.

Who are we?

TheraMe! a medtech spinoff from EPFL is at the forefront of advancing cancer treatment. TheraMe! AG was founded in 2023 with a successful seed round. Our journey is rooted in over a decade of academic research conducted in collaboration with a multinational consortium. This solid foundation drives our commitment to revolutionize cancer therapy through state-of-the-art microfluidic technology.

Internationally renowned experts and university professors in the fields of microfluidics, bioinformatics and clinical oncology work together at TheraMe!, having a single goal in mind: Identifying the very best treatment option for any cancer patient, at any stage of the disease!

Our mission to redefine cancer care. At TheraMe!, we're not just advancing medicine, we're transforming lives.

Are you ready to make a difference in the world and become part of our patient-centered team that is focused on making personalized cancer therapy possible?

Learn more about the career opportunities at TheraMe!